End-to-end automated manufacturing of low-seed CAR-T cells
Jun
27
2024
Upcoming webinar

End-to-end automated manufacturing of low-seed CAR-T cells

Thursday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST
Sponsor
End-to-end automated manufacturing of low-seed CAR-T cells

The pathway to commercial success requires viewing commercial readiness through several lenses, including scalability, process development and optimization, cost and labor management, and GMP compliance.

For example, in CAR-T cell production, the upstream process must allow for a broad dynamic range in terms of cell seeding density - for example, to cater for both pediatric and adult dosages. A detailed investigation into the expansion of genetically modified CAR-T cells on the Quantum Flex Cell Expansion System was recently completed as part of a strategic collaboration between BioCentriq and Terumo Blood and Cell Technologies. This presentation not only details the technical results of this study, but also the rapid technology transfer of an end-to-end manufacturing protocol to a contracted site.

Join this webinar to learn more about:

  • Data describing cell expansion kinetics of CAR-T cells and deep phenotypic characterization
  • Insights into the critical factors involved in the rapid technology transfer of an end-to-end manufacturing protocol to a contracted site
  • Results of cell killing assays and cytokine re-stimulation responses
David Smith
David Smith
Vice President at BioCentriq

With 15+ years of experience in the field of regenerative medicine, David’s proven expertise and background in engineering have led to a history of success in advancing cell therapy product manufacturing. His skills and experience include design of experiments, quality-by-design, R&D, data analysis, strong leadership, and cross-functional oversight, among many others. In his role at BioCentriq, he leads MS&T (Manufacturing, Science, And Technologies), Process Development, and Analytical Method Development. As the former Vice President of Technical Operations at Ori Biotech, David led the execution of the technical strategy for Ori’s first innovative technology play in cell therapy manufacturing. He was charged with ensuring the approach remained relevant to industry needs as it matured, requiring a multi-pronged approach to gather information, identify industry needs, align to viable solutions, build a cross-functional team, and support adoption. David’s other prior roles include serving as Director of Research and Development at Minaris Regenerative Medicine.